Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study

Clinical trial NCT06598527 · RECRUITING

Trial details

NCT number: NCT06598527
Sponsor: Yang Hong
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)

Start date: 2024-10-15
Primary completion: 2027-01-30
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.